CeriBell (NASDAQ:CBLL) Director Sells $537,250.00 in Stock

CeriBell, Inc. (NASDAQ:CBLL) Director Josef Parvizi sold 25,000 shares of the company’s stock in a transaction that occurred on Monday, December 15th. The shares were sold at an average price of $21.49, for a total value of $537,250.00. Following the completion of the transaction, the director directly owned 772,652 shares of the company’s stock, valued at approximately $16,604,291.48. This represents a 3.13% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Josef Parvizi also recently made the following trade(s):

• On Monday, December 8th, Josef Parvizi sold 25,000 shares of CeriBell stock. The stock was sold at an average price of $20.26, for a total value of $506,500.00.

CeriBell Stock Performance

CBLL stock traded down $0.40 during midday trading on Wednesday, reaching $21.59. 501,999 shares of the company’s stock traded hands, compared to its average volume of 612,782. CeriBell, Inc. has a 52 week low of $10.01 and a 52 week high of $28.43. The company has a 50-day moving average price of $14.90 and a two-hundred day moving average price of $14.61. The company has a debt-to-equity ratio of 0.12, a quick ratio of 12.25 and a current ratio of 12.65. The firm has a market capitalization of $800.99 million, a PE ratio of -14.30 and a beta of 1.35.

CeriBell (NASDAQ:CBLL) last released its quarterly earnings data on Tuesday, November 4th. The company reported ($0.37) EPS for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.06. The company had revenue of $22.59 million during the quarter, compared to analyst estimates of $21.78 million. CeriBell had a negative net margin of 63.35% and a negative return on equity of 29.63%. As a group, equities analysts anticipate that CeriBell, Inc. will post -2.46 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on CBLL shares. JPMorgan Chase & Co. lowered their price objective on CeriBell from $21.00 to $17.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 5th. Cowen reaffirmed a “buy” rating on shares of CeriBell in a report on Tuesday, December 9th. Canaccord Genuity Group boosted their price objective on CeriBell from $29.00 to $30.00 and gave the stock a “buy” rating in a report on Wednesday. Raymond James Financial initiated coverage on shares of CeriBell in a research report on Tuesday, October 21st. They set a “strong-buy” rating and a $19.00 target price for the company. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of CeriBell in a report on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $24.67.

Institutional Investors Weigh In On CeriBell

Institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. raised its position in CeriBell by 11.1% in the 3rd quarter. Vanguard Group Inc. now owns 1,473,856 shares of the company’s stock worth $16,935,000 after purchasing an additional 147,013 shares during the period. Yu Fan grew its stake in shares of CeriBell by 10.7% during the second quarter. Yu Fan now owns 1,353,166 shares of the company’s stock valued at $25,345,000 after buying an additional 130,964 shares during the last quarter. Novo Holdings A S increased its holdings in shares of CeriBell by 2.3% in the second quarter. Novo Holdings A S now owns 900,000 shares of the company’s stock worth $16,857,000 after buying an additional 20,000 shares during the period. TimesSquare Capital Management LLC lifted its stake in shares of CeriBell by 2.6% in the 3rd quarter. TimesSquare Capital Management LLC now owns 817,645 shares of the company’s stock valued at $9,395,000 after acquiring an additional 20,700 shares during the last quarter. Finally, Millennium Management LLC grew its position in CeriBell by 41.8% during the 3rd quarter. Millennium Management LLC now owns 666,448 shares of the company’s stock worth $7,657,000 after acquiring an additional 196,299 shares during the last quarter.

About CeriBell

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.